Cite

HARVARD Citation

    Hartung, H. et al. (2022). Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple sclerosis. pp. 429-440. [Online]. 
  
Back to record